The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization - PubMed
- ️Mon Jan 01 2001
. 2001 Oct 4;345(14):1030-5.
doi: 10.1056/NEJMoa010819.
Affiliations
- PMID: 11586955
- DOI: 10.1056/NEJMoa010819
Free article
The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization
V Dishy et al. N Engl J Med. 2001.
Free article
Abstract
Background: With continuous exposure to beta2-adrenergic agonists, vascular tissue becomes desensitized to agonist-mediated vasodilatation. We studied the effects of two common polymorphisms of the beta2-adrenergic receptor, one at codon 16 and one at codon 27, on agonist-mediated vasodilatation and desensitization in the vascular bed.
Methods: We studied 26 healthy subjects who were selected to represent three genotypes: 7 were homozygous for the alleles encoding Arg16 and Gln27, 8 were homozygous for the alleles encoding Gly16 and Gln27, and 11 were homozygous for the alleles encoding Gly16 and Glu27. Vascular responses were assessed by measuring changes in the diameter of a dorsal hand vein. A dose-response curve of the effect of the beta2-adrenergic-receptor agonist isoproterenol was constructed (dose range, 4 to 480 ng per minute). Desensitization was then induced by a 2-hour continuous infusion of isoproterenol, and venodilatation was measured 30, 60, 90, and 120 minutes after the start of the infusion.
Results: Subjects who were homozygous for Arg16 had almost complete desensitization; venodilatation in response to isoproterenol in this group decreased from a mean (+/-SE) of 44+/-11 percent to 8+/-4 percent (P=0.006). In contrast, subjects who were homozygous for Gly16 did not have significant desensitization, irrespective of the amino acid encoded by codon 27. Subjects who were homozygous for Glu27 had higher maximal venodilatation in response to isoproterenol than those who were homozygous for Gln27 (86+/-13 percent vs. 54+/-8 percent, P=0.03).
Conclusions: The Arg16 polymorphism of the beta2-adrenergic receptor is associated with enhanced agonist-mediated desensitization in the vasculature, and the Glu27 polymorphism is associated with increased agonist-mediated responsiveness. Therefore, polymorphisms of the beta2-adrenergic receptor are potentially important determinants of the vascular response to stress.
Comment in
-
Polymorphisms of the beta2-adrenergic receptor.
Liggett SB. Liggett SB. N Engl J Med. 2002 Feb 14;346(7):536-8. doi: 10.1056/NEJM200202143460718. N Engl J Med. 2002. PMID: 11844862 No abstract available.
Similar articles
-
Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo.
Bruck H, Leineweber K, Park J, Weber M, Heusch G, Philipp T, Brodde OE. Bruck H, et al. Clin Pharmacol Ther. 2005 Sep;78(3):232-8. doi: 10.1016/j.clpt.2005.06.002. Clin Pharmacol Ther. 2005. PMID: 16153394 Clinical Trial.
-
Khalaila JM, Elami A, Caraco Y. Khalaila JM, et al. Pharmacogenet Genomics. 2007 Oct;17(10):803-11. doi: 10.1097/FPC.0b013e3281eb8f07. Pharmacogenet Genomics. 2007. PMID: 17885618
-
Turnes J, Hernández-Guerra M, Abraldes JG, Bellot P, Oliva R, García-Pagán JC, Bosch J. Turnes J, et al. Hepatology. 2006 Jan;43(1):34-41. doi: 10.1002/hep.21000. Hepatology. 2006. PMID: 16374847
-
Ge D, Huang J, He J, Li B, Duan X, Chen R, Gu D. Ge D, et al. Ann Hum Genet. 2005 Jan;69(Pt 1):36-44. doi: 10.1046/j.1529-8817.2003.00093.x. Ann Hum Genet. 2005. PMID: 15638826 Review.
-
Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases.
Brodde OE. Brodde OE. Fundam Clin Pharmacol. 2008 Apr;22(2):107-25. doi: 10.1111/j.1472-8206.2007.00557.x. Fundam Clin Pharmacol. 2008. PMID: 18353108 Review.
Cited by
-
Duarte JD, Thomas CD, Lee CR, Huddart R, Agundez JAG, Baye JF, Gaedigk A, Klein TE, Lanfear DE, Monte AA, Nagy M, Schwab M, Stein CM, Uppugunduri CRS, van Schaik RHN, Donnelly RS, Caudle KE, Luzum JA. Duarte JD, et al. Clin Pharmacol Ther. 2024 Oct;116(4):939-947. doi: 10.1002/cpt.3351. Epub 2024 Jul 1. Clin Pharmacol Ther. 2024. PMID: 38951961 Free PMC article.
-
Pharmacogenetics in drug development.
McCarthy AD, Kennedy JL, Middleton LT. McCarthy AD, et al. Philos Trans R Soc Lond B Biol Sci. 2005 Aug 29;360(1460):1579-88. doi: 10.1098/rstb.2005.1688. Philos Trans R Soc Lond B Biol Sci. 2005. PMID: 16096107 Free PMC article. Review.
-
Gowdak MM, Laterza MC, Rondon MU, Trombetta IC, Pereira AC, Krieger JE, Negrão CE. Gowdak MM, et al. Lipids Health Dis. 2010 Jun 2;9:55. doi: 10.1186/1476-511X-9-55. Lipids Health Dis. 2010. PMID: 20515505 Free PMC article.
-
Pharmacogenomics: marshalling the human genome to individualise drug therapy.
Evans WE. Evans WE. Gut. 2003 May;52 Suppl 2(Suppl 2):ii10-8. doi: 10.1136/gut.52.suppl_2.ii10. Gut. 2003. PMID: 12651877 Free PMC article. Review.
-
Muszkat M, Kurnik D, Sofowora GG, Solus J, Xie HG, Harris PA, Williams SM, Wood AJ, Stein CM. Muszkat M, et al. J Hypertens. 2010 Feb;28(2):278-84. doi: 10.1097/HJH.0b013e328333d212. J Hypertens. 2010. PMID: 20051907 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases